Many patients who have undergone allogeneic hematopoietic stem cell transplantation (aHSCT) as part of cancer therapy achieve remission. However, nearly 50% of these patients develop Graft versus Host Disease (GVHD), a chronic autoimmune disease that can damage eyes. Quantifying specific cytokine changes in tears may reveal biomarkers and future treatment targets for ocular GVHD (oGVHD). Compared to other assays, the IsoLight Codeplex Secretome multiplex assay (Isoplexis) has advantages of high-throughput analyses and small sample requirements, but has yet to be validated for tears. This study evaluates the tears of a patient with oGVHD utilizing Isoplexis and correlates the cytokine profile with clinical disease severity.